RxDoctor Payments Data

Robert Cadogan, MD

Family Medicine · Columbia, MDNPI 1598767691

Payments from drug & device makers

$343in general payments, 2019–2025

Across 8 payments — averaging $42.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$125
  • Organogenesis Inc.$88
  • Orexo US, Inc.$46
  • Philips North America LLC$45
  • Lilly USA, LLC$19
  • AstraZeneca$19

What the payments were for

  • Food & beverage$343100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$343 in reported general payments places this provider in the 50th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$113,538
Medicare patients
382
Services billed
3,163

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin36$42,018
JanuviaSitagliptin Phosphate29$38,439
OzempicSemaglutide24$30,368
EliquisApixaban23$26,240
GemtesaVibegron23$12,085
Breo ElliptaFluticasone/Vilanterol17$6,773
LinzessLinaclotide11$6,330
Atorvastatin Calcium347$5,598
Fluticasone-SalmeterolFluticasone Propion/Salmeterol20$5,287
Tresiba Flextouch U-100Insulin Degludec13$4,085
Metoprolol Succinate218$3,659
Carbamazepine ErCarbamazepine14$2,990
Rosuvastatin Calcium119$2,880
Amlodipine Besylate292$2,302
Losartan Potassium136$2,240

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCOlanzapine$19$60711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Columbia

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →